State dependent dissociation of HERG channel inhibitors by Stork, D. et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
State dependent dissociation of HERG channel inhibitors
Citation for published version:
Stork, D, Timin, EN, Berjukow, S, Huber, C, Hohaus, A, Hering, S & Auer, M 2007, 'State dependent
dissociation of HERG channel inhibitors' British Journal of Pharmacology, vol 151, no. 8, pp. 1368-1376.
DOI: 10.1038/sj.bjp.0707356
Digital Object Identifier (DOI):
10.1038/sj.bjp.0707356
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
British Journal of Pharmacology
Publisher Rights Statement:
OnlineOpen Article
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 28. Apr. 2017
RESEARCH PAPER
State dependent dissociation of HERG channel
inhibitors
D Stork1, EN Timin1, S Berjukow1, C Huber1, A Hohaus1, M Auer2 and S Hering1
1Department of Pharmacology and Toxicology, University of Vienna, Vienna, Austria and 2Novartis Institute for Biomedical Research
Vienna Discovery Technologies, Innovative Screening Technologies, Vienna, Austria
Background and purpose: Inhibition of HERG channels prolongs the ventricular action potential and the QT interval with the
risk of torsade de pointes arrhythmias and sudden cardiac death. Many drugs induce greater inhibition of HERG channels when
the cell membrane is depolarized frequently. The dependence of inhibition on the pulsing rate may yield different IC50 values
at different frequencies and thus affect the quantification of HERG channel block. We systematically compared the kinetics of
HERG channel inhibition and recovery from block by 8 blockers at different frequencies.
Experimental approach: HERG channels were expressed heterologously in Xenopus oocytes and currents were measured with
the two-electrode voltage clamp technique.
Key results: Frequency-dependent block was observed for amiodarone, cisapride, droperidol and haloperidol (group 1)
whereas bepridil, domperidone, E-4031 and terfenadine (group 2) induced similar pulse-dependent block at all frequencies.
With the group 1 compounds, HERG channels recovered from block in the presence of drug (recovery being voltage-
dependent). No substantial recovery from block was observed with the second group of compounds. Washing out of bepridil,
domperidone, E-4031 and terfenadine was substantially augmented by frequent pulsing. Mutation D540K in the HERG
channel (which exhibits reopening at negative voltages) facilitated recovery from block by these compounds at 140 mV.
Conclusion and implications: Drug molecules dissociate at different rates from open and closed HERG channels (‘use-
dependent’ dissociation). Our data suggest that apparently ‘trapped’ drugs (group 2) dissociated from the open channel state
whereas group 1 compounds dissociated from open and resting states.
British Journal of Pharmacology (2007) 151, 1368–1376; doi:10.1038/sj.bjp.0707356; published online 25 June 2007
Keywords: HERG; drug trapping; use-dependent block; HERG channel blocker
Abbreviations: cDNA, complementary deoxyribonucleic acid; cRNA, complementary ribonucleic acid; HERG, human ether-a-
go-go related gene; KMes, 2-(N-morpholino)ethanesulphonic acid potassium salt; LQTS, long QT syndrome ;
NaMes, 2-(N-morpholino)ethanesulphonic acid sodium salt; nH, Hill coefficient; QSAR, quantitative structure–
activity relationship; TdP, torsade de pointes
Introduction
The human ether-a-go-go-related gene (HERG) encodes a
delayed rectifier Kþ channel that plays a pivotal role during
the repolarization phase of the cardiac action potential
(Sanguinetti et al., 1995; Trudeau et al., 1995; Tseng, 2001;
Vandenberg et al., 2001). Mutations in HERG leading to
partial or complete loss of function prolong the ventricular
action potential and may cause the dominantly inherited
long QT syndrome with the risk of life-threatening torsade de
pointes (TdP) arrhythmias and sudden cardiac death (Curran
et al., 1995; Keating and Sanguinetti, 2001; Sanguinetti and
Mitcheson, 2005). TdP is more often caused by drug-induced
HERG channel inhibition. HERG channel block is a key
factor in the pro-arrhythmic liability of a wide range of
chemically diverse drugs (Redfern et al., 2003; Sanguinetti
and Mitcheson, 2005). Several drugs have been withdrawn
from the market or have had their use restricted because of
this effect (Redfern et al., 2003; De Bruin et al., 2005). The
apparent link between HERG channel block and ventricular
arrhythmias has prompted extensive screening studies
during drug development. The risk that a drug will induce
LQT has been assessed by recording action potentials in
single myocardial cells and multicellular myocardial pre-
parations, and ECG measurements of the QT prolongation in
animals (Fermini and Fossa, 2003; Recanatini et al., 2005;
http://www.fda.gov/cber/gdlins/iche14qtc.htm).
An important indicator for possible arrhythmogenic
liability of a given compound is the inhibition of HERG
currents in heterologous expression systems. This inhi-
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bition is conventionally quantified as the concentration of
half-maximal inhibition (IC50). Many HERG channel block-
ers exhibit a use-dependent action indicating that drug binds
to open and/or inactivated channels with higher affinities
than to resting channels. The level of channel block depends
therefore not only on the drug concentration, but also on
the pulse protocol (Kirsch et al., 2004). Also, the degree of
block is considerably temperature-dependent (Kirsch et al.,
2004). These factors may account for the considerable
discrepancies between the IC50 values measured in different
laboratories (Pearlstein et al., 2003; Kirsch et al., 2004).
Verapamil (Waldegger et al., 1999; Zhang et al., 1999),
amitriptyline (Jo et al., 2000), nifekalant (Kushida et al.,
2002) and trifluoperazine (Choi et al., 2005) inhibit HERG
more strongly at higher frequencies. HERG channel block by
the antifungal miconazole (Kikuchi et al., 2005) or dofetilide
(Tsujimae et al., 2004) is facilitated by pulsing, but in a
frequency-independent manner. Previous studies suggested
that ‘lack of frequency dependence’ could be caused by
ultraslow recovery of HERG channels from block (see
Tsujimae et al., 2004; Kikucki et al., 2005).
Here, we systematically analyse ‘use-dependent’ block and
recovery from block of HERG channels with eight known
inhibitors. Four ‘group 1’ compounds – amiodarone, halo-
peridol, droperidol and cisapride – inhibited the currents in a
frequency-dependent manner and the HERG channels
completely recovered from block within 1.5 to 3 min. HERG
inhibition by E-4031, bepridil, domperidone and terfenadine
occurred with similar kinetics at all pulse frequencies
(frequency-independent block) and the channels exhibited
no significant recovery at rest.
Washout of E-4031, bepridil, domperidone and terfena-
dine (group 2 compounds) was accelerated substantially by
repetitive stimulation. Thus in addition to use-dependent
binding, our data suggest the ‘use-dependent dissociation’ of
these drugs.
Materials and methods
Molecular biology
Preparation of stage V–VI oocytes from Xenopus laevis
(NASCO, Fort Atkinson, WI, USA), synthesis of capped
runoff complementary ribonucleic acid (cRNA) transcripts
from linearized complementary deoxyribonucleic acid
(cDNA) templates and injection of cRNA were performed as
described in detail by Grabner et al. (1996). cDNAs of HERG
(accession number NP_000229) were kindly provided by Dr
Sanguinetti (University of Utah, UT, USA).
Voltage clamp analysis
Currents through HERG channels were studied 1–2 days after
microinjection of the cRNA using the two-microelectrode
voltage clamp technique. The bath solution contained
96 mM sodium chloride, 2 mM potassium chloride (KCl),
1 mM magnesium chloride (MgCl2), 5 mM HEPES (pH 7.5,
titrated with NaOH), 1.8 mM CaCl2 (Sigma-Aldrich
Chemie GmbH, Taufkirchen, Germany). The D540K mutant
channel was studied in low chloride solution: 96 mM
2-(N-morpholino)ethanesulphonic acid sodium salt, 2 mM
2-(N-morpholino)ethanesulphonic acid potassium salt, 1 mM
CaCl2, 5 mM HEPES and 1 mM MgCl2 adjusted to pH 7.6 with
methanesulphonic acid.
Voltage-recording and current-injecting microelectrodes
were filled with 3 M KCl, 10 mM HEPES (pH 7.4) and had
resistances between 0.3 and 2 MO. Endogeneous currents
(estimated in oocytes injected with water) did not exceed
0.15 mA. Currents 43mA were discarded to minimize voltage
clamp errors. A precondition for all measurements was the
achievement of stable peak current amplitudes over periods
of 10 min after an initial runup. All drugs were applied by
means of a new perfusion system enabling solution ex-
change within about 100 ms (Baburin et al., 2006).
The pClamp software package version 8.0 (Axon Instru-
ments Inc., Union City, CA, USA) was used for data
acquisition. Microcal Origin 7.0 was employed for analysis
and curve fitting.
Estimation of half-maximal inhibition of HERG channels
None of the compounds induced significant resting state
block. The amount of inhibition during 3 min preincubation
was either absent or very small (o10%). Use-dependent
HERG channel block was estimated as peak tail current
inhibition. The tail currents were measured at 40 mV, after
a step to þ20 mV. The concentration–inhibition curves were
fitted using the Hill equation
IHERG;drug=IHERG;control ¼ ð100  AÞ=ð1 þ ðC=IC50ÞnHÞ þ A;
where IC50 is the concentration at which HERG inhibition is
half-maximal, C is the applied drug concentration, A is the
fraction of HERG current that is not blocked and nH is the
Hill coefficient.
Data analysis
Data points represent means7s.e. from at least three oocytes
from X2 batches; statistical significance of differences was
defined as Po0.05 in Student’s unpaired t-test.
Drugs
The studied compounds (amiodarone, bepridil, cisapride,
domperidone, droperidol, E-4031, haloperidol and terfena-
dine (provided by the Novartis Institute for Biomedical
Research, Vienna, Austria, Innovative Screening Technolo-
gies)) were dissolved in dimethyl sulphoxide (DMSO) to
prepare a 10 mM stock and stored at 201C. Drug stocks were
diluted to the required concentration in extracellular solu-
tion on the day of each experiment. The maximal DMSO
concentration in the bath (0.1%) did not affect HERG
currents.
Results
We investigated inhibition of HERG channels by eight
known blockers during pulse trains as described in Figure 1
(see inset in Figure 1b). The voltage protocol was designed to
HERG channel block
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simulate voltage changes during a cardiac action potential
with a 300 ms depolarization to þ20 mV (analogous to
plateau phase), a repolarization for 300 ms to 40 mV
(inducing a tail current) and a final step to the holding
potential. The þ20 mV depolarization rapidly inactivates
HERG channels, thereby limiting the amount of outward
current. During the repolarization to 40 mV, the previously
activated channels open due to rapid recovery from
inactivation. The resulting tail current amplitudes were
taken as a measure of block development during a pulse
train. The kinetics of peak tail current inhibition are given in
pulse numbers.
Different kinetics of HERG channel inhibition during
0.3 Hz trains of pulses by haloperidol, bepridil, domperidone
and E-4031 are illustrated in Figure 1. Peak currents decayed
either very slowly reaching steady-state inhibition within
180 pulses (E-4031), or rapidly within five pulses (haloper-
idol).
Effects of pulse frequency on HERG channel inhibition
In general, state-dependent drug action would predict
enhanced HERG current inhibition during repetitive pulsing
and increase of frequency is expected to deepen channel
block. Indeed, Figure 2a shows stronger HERG channel
inhibition by amiodarone (10 mM) at increasing frequencies
(from 0.1 to 1 Hz) (see also Kiehn et al., 1999). Development
of block is illustrated by plotting peak current values against
pulse number at different frequencies (0.03–1 Hz, Figure 2b).
Frequency-dependent inhibition was observed for cisapride
(3 mM, Figure 2c; see also Walker et al., 1999), haloperidol
(3 mM, Figure 2c; see also Suessbrich et al., 1997) and
droperidol (2mM, Figure 2c) (see ‘frequency-dependent
drugs’, Table 1, for steady-state inhibitions at different
frequencies).
A different pattern was observed for domperidone (3 mM).
Figure 3a shows that over a 10-fold range of stimulation
frequency (from 0.1 to 1 Hz), current inhibition remained
identical. This is confirmed by the superimposed peak
current decays during trains of different frequencies
(Figure 3b). Bepridil (3 mM, Figure 3c), E-4031 (10 mM,
Figure 3c; see also Ishii et al., 2003) and terfenadine (1mM,
Figure 3c; see also Suessbrich et al., 1996) all inhibited HERG
currents to a similar extent and with similar kinetics at all
frequencies (see ‘frequency-independent’ blockers, Table 1).
Recovery from block at rest
Gradual decay of HERG currents during a pulse train is
traditionally considered to reflect the equilibration between
state-dependent drug binding during depolarization and
recovery at rest. To elucidate the kinetic fingerprints of the
two groups (Figure 2 vs Figure 3) in more detail, we
investigated the recovery processes over longer periods
(Figure 4).
Channel block was induced by applying 1 Hz conditioning
trains of different length until steady state was reached (see
Figure 1). HERG currents were subsequently measured after a
330 s rest period. HERG channels recovered completely from
block by amiodarone, haloperidol, droperidol and cisapride.
Minor recovery was observed in the presence of E-4031
(1170.9%), bepridil (4.370.5%), domperidone (1571.2%)
and terfenadine (270.3%), (Figure 4c).
Recovery with group 1 compounds was analysed in more
detail. Test pulses were applied after rest periods of 10, 30, 60,
120, 210 or 330 s at different holding potentials (Figure 5).
Recovery from block was monoexponential and accelerated
at more negative voltages. Amiodarone, droperidol and
haloperidol dissociated with similar kinetics, while cisapride
dissociated somewhat faster. The time constants at 80,
100 and 120 mV are given in Table 2.
Channel activation accelerates recovery from block during
‘washout’
Steady-state inhibition during a pulse train reflects a balance
between drug binding during channel opening and dissocia-
tion. For amiodarone, haloperidol, cisapride and droperidol,
the steady state of HERG inhibition results from open
channel block and subsequent recovery during the
Figure 1 Different kinetics of human ether-a-go-go-related gene (HERG) channel inhibition. (a) The development of channel inhibition by
haloperidol (3mM), bepridil (3mM), compound E-4031 (3mM) and domperidone (3mM) during repetitive stimulation at a frequency of 0.3 Hz.
Pulse trains were applied after a 3 min equilibration period in drug without stimulation. HERG currents were evoked by a repolarizing step to
40 mV after a 300 ms conditioning pulse to 20 mV (see inset in b). Peak HERG tail currents are plotted vs pulse number during a train. Steady-
state inhibition by E-4031 was achieved after 180 pulses (see interrupted x axis) whereas steady-state block by haloperidol occurred within five
pulses. (b) Representative currents illustrating the difference on rates. Ultra-slow inhibition of HERG current by E-4031 is illustrated by plotting
every 10th current.
HERG channel block
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interpulse period at rest. Such a scenario is, however,
unlikely for domperidone, bepridil, E-4031 and terfenadine.
The lack of recovery between the individual pulses during
a 0.1 Hz train suggests that the steady-state inhibition
(Figure 3, Table 1) is due to drug dissociation from open
channels.
We analysed whether frequent channel activation (open-
ing) would accelerate recovery in drug-free solution during
washout. Higher frequency pulsing (1 Hz) induced faster
restoration of HERG currents than lower frequency pulsing
(0.03 Hz). Typical experiments are illustrated in Figure 6.
Repetitive activation at 1 Hz induced complete recovery
during 2 min of washout of domperidone, 5 min with
bepridil, 15 min with E-4031 and 17 min with terfenadine.
Lower frequency stimulation (0.03 Hz) induced slower
recovery during washout. If the channels were not activated
(that is, remained in the closed state) we observed very slow
recovery in drug-free solution (Figure 6).
Mutation D540K enables dissociation of group 2 compounds at
strong hyperpolarizations
HERG channels with the D540K mutation reopen in
response to membrane hyperpolarization (Mitcheson et al.,
2000). The unique gating behaviour of this mutant allows
drugs that are otherwise trapped inside the central cavity to
leave the reopened channel at negative potentials. To study
the recovery from block by group 2 compounds, we used the
voltage protocol shown at the top of Figure 7a. Voltage
pulses to 0 mV (5 s duration) were repeatedly applied at 15 s
intervals. After 20 depolarizing pulses to 0 mV, 20 hyperpo-
larizing pulses to 140 mV (5 s duration, 15 s interval) were
applied in the presence of terfenadine or domperidone
(Figure 7), followed by a depolarizing pulse to 0 mV to
estimate recovery from block. The percentage of recovery
was estimated as x¼ (eb)/(ab)100. The percentages of
recovery were 86.577.3% (n¼4) for terfenadine and
93.374.0% (n¼4) for domperidone. Similar recovery levels
Figure 2 Frequency-dependent human ether-a-go-go-related gene channel inhibition. (a) Representative current traces during pulse trains of
indicated frequencies in the presence of amiodarone (10mM). The voltage protocol is shown in the inset (top left). Normalized peak current
values are plotted against pulse number for (b) amiodarone (10 mM) and (c) haloperidol (3mM), cisapride (3mM) and droperidol (2 mM). Lines
represent fit to single exponential functions (Ipeak¼A exp(N/Nconst)þ Iss). The steepness parameters Nconst and steady-state levels are given in
Table 1.
Table 1 Rate and steady-state level of HERG channel inhibition at
different frequencies (see Figures 2–4)
Compound Frequency (Hz) Rate of block (in no.
of pulses)
Steady state
Amiodarone 0.03 (n¼4) 1.4570.25 0.8470.01
(10 mM) 0.1 (n¼5) 2.5670.23 0.6970.04
0.3 (n¼4) 2.7470.27 0.5270.08
1.0 (n¼4) 3.4470.54 0.4670.08*
Haloperidol (3 mM) 0.03 (n¼3) 1.5870.37 0.5070.08
0.1 (n¼4) 1.2470.18 0.4870.02
0.3 (n¼4) 1.1970.25 0.4470.02
1.0 (n¼5) 1.2070.33 0.3970.02*
Cisapride (3 mM) 0.1 (n¼5) 2.4970.53 0.5370.06
0.3 (n¼4) 1.5970.17 0.3770.06
1.0 (n¼5) 2.0570.38 0.2370.06*
Droperidol (2 mM) 0.03 (n¼6) 2.1470.50 0.6670.25
0.1 (n¼6) 1.4770.27 0.5470.03
0.3 (n¼8) 1.4670.13 0.5070.23
1.0 (n¼7) 1.4870.23 0.4770.03*
Bepridil (3 mM) 0.1 (n¼3) 1.9270.20 0.4370.02
0.3 (n¼3) 3.1370.28 0.4070.02
1.0 (n¼3) 3.1670.31 0.3670.04
E-4031 (10 mM) 0.03 (n¼3) 29.4976.68 0.2570.05
0.1 (n¼3) 60.6673.33 0.1270.02
1.0 (n¼3) 34.1270.74 0.2570.01
Domperidone 0.1 (n¼3) 2.0670.26 0.5970.05
(3 mM) 0.3 (n¼3) 1.7570.6 0.5770.04
1.0 (n¼3) 1.8870.12 0.4970.03
Terfenadine (1 mM) 0.1 (n¼6) 34.1279.88 0.3270.06
0.3 (n¼4) 28.975.78 0.4270.02
1.0 (n¼4) 17.5370.31 0.3670.02
*Indicates statistically significant (Po0.05) differences between steady-state
inhibition at low (0.03 or 0.1 Hz) and high (1 Hz) frequency.
HERG channel block
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(current traces are not shown) were observed for E-4031
(62.779.3%, n¼4) and bepridil (68.3710.5%, n¼3).
Discussion and conclusions
In the present study, we analysed the recovery kinetics of
HERG after ‘use-dependent’ inhibition by eight channel
blockers. Amiodarone, cisapride, haloperidol and droperidol
exhibited frequency-dependent block of HERG channels
(Figure 2, Table 1). These drugs inhibited HERG channels
more efficiently at higher stimulation frequencies. No
enhancement of channel inhibition at higher frequencies
was observed for bepridil, terfenadine, E-4031 and domper-
idone (Figure 3, Table 1). Kikuchi et al. (2005) described a
similar kinetic phenotype of HERG inhibition by micona-
zole, with ultra-slow recovery at rest. Our data clearly show
that pulse-dependent but frequency-independent HERG
inhibition by bepridil, terfenadine, E-4031 and domperidone
also results from ultra-slow recovery (Figure 4). These
findings are in line with the hypothesis that some drug
molecules (that is, group 2 compounds) are trapped by
channel shutting (Armstrong, 1971; Carmeliet, 1992; Mitch-
eson et al., 2000). Frequent depolarizations during washout
or reopening at strong hyperpolarization (mutant D540K)
allowed the trapped drug molecules to leave the channel
(Figures 6 and 7).
Different onset kinetics of ‘use-dependent’ HERG inhibition
We observed remarkably different kinetics for development
of block during pulse trains under comparable experimental
conditions (that is, at drug concentrations inducing between
40 and 60% of current inhibition at the same frequency,
Figure 1). Under these conditions, steady-state HERG inhibi-
tion by haloperidol and domperidone developed within 4–5
pulses, by amiodarone within 10–12 pulses, but with
compound E-4031 only after more than 120 pulses. Similar
steady-state levels of channel block and different kinetics point
towards drug-specific rates of association and dissociation.
Evidence for drug dissociation from the open state
Several lines of evidence support the hypothesis that
bepridil, domperidone, E-4031, terfenadine as well as
miconazole (Kikuchi et al., 2005) fail to recover at rest but
are able to dissociate from the open state. First, pulse-
dependent HERG channel inhibition by miconazole (Kiku-
chi et al., 2005), bepridil (Figure 3), terfenadine (Figure 3;
Suessbrich et al., 1996), E-4031 (Figure 3; Ishii et al., 2003)
and domperidone (Figure 3) reaches similar steady-state
levels at different train frequencies. If the equilibration
between channel blocking and unblocking is not affected by
drug dissociation at rest (see Figure 4 illustrating negligible
recovery within 330 s; see also Ishii et al., 2003), then these
compounds must dissociate from open HERG channels. In
other words, steady-state inhibition in Figure 3 is likely to
reflect the equilibrium between binding to, and dissociation
from, open channels.
More evidence for open-state dissociation comes from the
acceleration of washout by repetitive pulsing. Negligible
recovery during washout occurred when the channels
remained exclusively in the closed channel conformation
(Figure 6). Channel unblocking was facilitated by repetitive
pulsing at 0.03 Hz, and to a larger extent, at 1 Hz.
The data of Kamiya et al. (2006) suggest that E-4031 and
bepridil are trapped inside the pore when the activation gate
is shut. Reopening at negative voltages (in their study at
160 mV) allowed both compounds to dissociate. Here, we
obtained similar results for terfenadine and domperidone
(Figure 7) and confirmed previous findings of Kamiya et al.
(2006) for bepridil and E-4031 (traces not shown).
Figure 3 Frequency-independent human ether-a-go-go-related gene channel inhibition. (a) Representative current traces during pulse trains
of indicated frequencies in the presence of domperidone (3mM). The voltage protocol is the same as in Figure 2. Normalized peak current
values are plotted vs pulse number for (b) domperidone; (c) bepridil (3mM), E-4031 (10mM, every 10th pulse is shown) and terfenadine (1mM,
every 10th current is shown). Lines represent fits to single exponential functions (Ipeak¼A  exp(N/Nconst)þ Iss). The steepness parameters
Nconst and steady-state levels are given in Table 1.
HERG channel block
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Resting state dissociation of ‘frequency-dependent’ blockers
Group 1 compounds dissociate from closed HERG channels.
This is evident from Figures 4 and 5, which show recovery in
the presence of drug at rest. Recovery was gradually
accelerated by hyperpolarization (Table 2).
In general, group 1 compounds have two possibilities to
leave the closed channel. In one scenario, the drug exits the
channel only when the channel flickers to an open
conformation. This scenario is unlikely. Stronger hyper-
polarization decreases the probability of channel flickering
to an open conformation. Figure 5 shows, however, facilita-
tion of channel unblocking at more hyperpolarized voltages.
In a second scenario, channel closure does not completely
trap the drug (‘foot in the door’ mechanism; Armstrong,
1971) but it presents a barrier that the drug must pass before
dissociation. Our data support such a hypothesis, in which
(presumably bulky) gate structures create a barrier resulting
in pronounced voltage dependence of drug dissociation. In
other words, larger voltage drops across the closed channel
gates apparently ease the release of the charged group 1
compounds from the closed HERG channel state.
Drug trapping
Kamiya et al. (2006) suggest that gating structures may trap
drug molecules during channel closure. Ultra-slow recovery
from block at rest has been observed previously in cardiac
myocytes for IKr block by methanesulphonanilides (dofeti-
lide, MK-499; Carmeliet, 1992). More direct evidence for
drug trapping was provided by Mitcheson et al. (2000), using
Figure 4 Recovery of human ether-a-go-go-related gene channel
from block at rest. Channel block was induced by 1 Hz pulse trains
(see inset and Figure 1). Ten conditioning pulses were applied to
reach steady-state inhibition by amiodarone, cisapride, haloperidol,
droperidole, domperidone, bepridil. A total of 100 pulses were
required for E-4031 and terfenadine. Single test pulses were applied
after a 330 s rest at 80 mV. All experiments were performed in the
continued presence of drug. (a) Recovery from block by 10mM
amiodarone. Superimposed current traces were elicited by the 10th
pulse of the conditioning train (0 s) and a single test pulse after a
330 s rest at 80 mV. (b) Lack of recovery from block by 3 mM
bepridil. Superimposed traces of the current during the 10th pulse
and the test pulse after the 330 s rest period at 80 mV. (c) Recovery
after 330 s from block by amiodarone (n¼7), cisapride (n¼9),
haloperidol (n¼7), droperidol (n¼6), domperidone (n¼3), bepridil
(n¼3), E-4031 (n¼3) and terfenadine (n¼3).
Figure 5 Recovery from human ether-a-go-go-related gene chan-
nel block at different holding potentials. Recovery (normalized to
maximum current amplitude in drug, see a and b) plotted vs
recovery time. Solid lines are mono-exponential fits for recovery (a)
in 10mM amiodarone, (b) in 3 mM cisapride, (c) in 2 mM droperidol
and (d) in 3 mM haloperidol at 80, 100 and 120 mV. The time
constants (trecovery) are given in Table 2. A rest period of 5 min was
introduced between each recovery protocol.
Table 2 Time constant of recovery (s) at different holding potentials
Holding potential (mV) Amiodarone (10 mm) Cisapride (3 mm) Droperidol (2 mm) Haloperidol (3 mm)
80 66.472.8 s (n¼7) 50.774.2 s (n¼9) 61.575.6 s (n¼6) 66.476.1 s (n¼7)
100 46.873.58 s* (n¼3) 29.372.5 s* (n¼5) 35.875.1 s* (n¼4) 54.772.6 s* (n¼5)
120 34.372.1 s* (n¼3) 24.373.4 s* (n¼6) 26.072.5 s* (n¼5) 40.973.2 s* (n¼4)
*Indicates statistically significant (Po0.05) differences compared to the respective time constant at 80 mV.
HERG channel block
D Stork et al 1373
British Journal of Pharmacology (2007) 151 1368–1376
the HERG mutant D540K, which reopens during pro-
nounced hyperpolarization, thereby accelerating recovery
from block. Similar observations were made for propafenone
(Witchel et al., 2004). Interestingly, even strong hyperpolar-
izations do not facilitate recovery of frequency-independent
blockers from wild-type channels (for example, bepridil and
E-4031; Kamiya et al., 2006).
A significant acceleration of the washout of these com-
pounds by repetitive stimulation as described for bepridil,
terfenadine, E-4031 and domperidone in the present study
supports the view that trapped drugs may leave the open
channel at depolarized voltages. At the moment it is not
clear why some drugs are unable to leave the closed channel
state but other compounds dissociate. Hence, similar
residues were found to be crucial for binding of cisapride
and terfenadine (Sanguinetti and Mitcheson, 2005). Cisa-
pride belongs, however, to the group of frequency-depen-
dent blockers, while terfenadine dissociates with ultra-slow
kinetics resulting in frequency-independent block (Table 1).
We calculated several descriptors related to size, volume,
lipophilicity and accessible surface (data not shown).
Irrespective of the descriptor, amiodarone and terfenadine
always were similar in values. No trend that would allow to
group the compounds into trapped/non-trapped on basis of
one of the descriptors could be observed. However, the group
of compounds tested is by far too small and structurally too
heterogeneous to draw quantitative conclusions. A study
Figure 6 Repetitive stimulation accelerates washout of group 2
compounds. (a–d) Washout at a holding potential of 80 mV during
infrequent pulsing (test pulses applied with an interval of 10 min),
during 0.03 Hz pulsing and frequent stimulation at 1 Hz. Peak
currents were normalized to the control (the tail current amplitude
before application of drug).
Figure 7 Onset and recovery from block of the human ether-a-go-go-related gene (HERG) channel mutant D540 K by 3 mM terfenadine
(a) and 10mM domperidone (b). Channel block induced by repetitive pulsing to 0 mV (20 pulses after 3 min of equilibration without pulsing)
is recovered from repetitive pulsing to 140 mV. Top: voltage protocol (5 s pulses to 0 or 140 mV, applied at 15 s intervals). Middle:
Representative current traces. Labels a, b: superimposed 1st and 20th traces during the train of depolarizing pulses to 0 mV. Labels c and d: 1st
and 20th traces during the train of hyperpolarizing pulses to 140 mV. Label e: 1st trace after recovery. Bottom: Plot of peak outward HERG
current against pulse number.
Figure 8 Concentration/inhibition curves for the frequency-depen-
dent inhibitor amiodarone (a) and the frequency-independent
inhibitor domperidone (b). Human ether-a-go-go-related gene
currents were evoked by either 0.03 or 1 Hz trains. Steady-state
values of peak tail current are plotted against drug concentration.
The IC50 values for amiodarone were 7.1772.05mM, nH¼1.4,
(0.03 Hz) and 1.0870.65mM, nH¼1.43 (0.3 Hz). The corresponding
values for domperidone were 4.671.4mM, nH¼2.29 (0.03 Hz) and
5.670.4mM, nH¼1.47 (0.3 Hz).
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using a systematically modified set of compounds is
currently in progress.
Impact on IC50 estimation
Four compounds (amiodarone, cisapride, haloperidol and
droperidol) were found to block HERG channels in a
frequency-dependent manner and four others (bepridil,
terfenadine, E-4031 and domperidone) inhibited the cur-
rents to a similar degree and with similar kinetics at all
frequencies. Figure 8 illustrates the consequences for quanti-
fication of drug/channel interactions. Amiodarone belongs
to group 1 (frequency-dependent) and domperidone to
group 2 (frequency-independent). The concentration/inhibi-
tion curves for both compounds were measured with pulse
trains of either 0.03 or 0.3 Hz. The IC50 values of HERG
current inhibition for amiodarone were 7.272.05 mM at
0.03 Hz and 1.170.65 mM at 0.3 Hz. The IC50 values for
domperidone were similar at both frequencies (E5mM).
Thus, among other factors such as temperature and pulse
pattern (Kirsch et al., 2004), the frequency of membrane
depolarization may or may not affect the estimation of IC50
values.
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